*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.**
**杭州九源基因生物醫藥股份有限公司**
*(A joint stock company incorporated in the People's Republic of China with limited liability)*
**(Stock code: 2566)**

# MONTHLY UPDATE ANNOUNCEMENT IN RELATION TO PUBLIC FLOAT

Reference is made to the announcement of Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd. (the "**Company**") dated March 5, 2026 (the "**Announcement**") and the supplemental announcement of the Company dated March 25, 2026 (the "**Supplemental Announcement**") in relation to its public float. Unless otherwise specified, capitalized terms used herein shall have the same meanings as those defined in the Announcement and the Supplemental Announcement.

## MONTHLY UPDATE

The Board wishes to update the Shareholders and potential investors of the Company that, as at the date of this announcement, the public float of the Company is approximately 22.22%, which remains below the Minimum Prescribed Percentage as prescribed by Rule 19A.28B of the Listing Rules.

The Company is implementing the public float restoration plan (i.e. the H Share Full Circulation) in accordance with the expected timetable set out in the Supplemental Announcement and will use its best endeavours to restore its public float within the second quarter of 2026.

The H Share Full Circulation was approved at the Company's extraordinary general meeting held on December 22, 2025. The Company submitted the Filing Application to the CSRC on December 23, 2025, and the CSRC issued a filing notice to the Company in respect of the H Share Full Circulation on April 2, 2026. According to the Filing Notice, the filing with the CSRC in relation to the H Share Full Circulation, in respect of the conversion of 136,302,015 Unlisted Shares held by 12 shareholders of the Company into H shares has been completed. The Company shall update the filing materials with the CSRC and apply to the Stock Exchange for the listing of, and permission to deal in, such H Shares on the Main Board

of the Stock Exchange. Upon completion of the H Share Full Circulation and assuming there is no other change in the shareholding of the Company's core connected persons, the public float is expected to increase to approximately 31.13%, thereby restoring compliance with the Minimum Prescribed Percentage.

To strengthen its internal control procedures and avoid any recurrence of similar incidents in the future, the Company will continue to:

(a) enhance the securities dealing clearance procedures for Directors and their respective close associates by incorporating a public float impact assessment into the approval process. No clearance will be granted for any dealing that could result in (or further worsen) a public float shortfall;

(b) conduct monthly review of the Company's shareholding structure, including the register of members and Disclosure of Interests filings on the Stock Exchange's website and will promptly report any potential public float issue to the Board for consideration and, where appropriate, make timely disclosure and take remedial action;

(c) incorporate refresher briefing into its annual training sessions for Directors on (i) the minimum public float requirement under the Listing Rules; (ii) directors' securities dealing procedures in accordance with the Model Code for Securities Transactions by Directors of Listed Issuers as set out in Appendix C3 to the Listing Rules; and (iii) disclosure of interests; and

(d) maintain centralized and updated records of all treasury Shares and repurchased Shares. The impact of these Shares on the public float position will be assessed on an ongoing basis to ensure continuous compliance.

Further announcement(s) will be made by the Company on a monthly basis until the public float of the Company is restored to the Minimum Prescribed Percentage in accordance with the Listing Rules, so as to keep Shareholders and the market informed on the progress made in carrying out the proposed public float restoration plans.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the Shares.**

By order of the Board
**Hangzhou Jiuyuan Genetic Biopharmaceutical Co., Ltd.**
**杭州九源基因生物醫藥股份有限公司**
**FU Hang**
*Executive Director, Chairman of the Board and General Manager*

Hangzhou, the PRC, April 8, 2026

*As of the date of this announcement, the Board comprises (i) Mr. Fu Hang (傅航) and Mr. Zhou Wei (周偉) as executive directors; (ii) Mr. Wu Shihang (吳詩航), Mr. Albert Esteve Cruella, Mr. Fei Junjie (費俊傑) and Ms. Yan Weiting (嚴瑋婷) as non-executive directors; and (iii) Mr. Zhou Zhihui (周智慧), Ms. Ho Mei Yi (何美儀) and Dr. Zhou Demin (周德敏) as independent non-executive directors.*